Israeli company Galmed Pharmaceuticals Ltd., which is developing proprietary drugs for the treatment of fatty liver disease, is planning a multi-million IPO at a company value of $100 million. “Globes” reports that the decision will be made by October, and if the decision is taken to go ahead, the IPO will be held in December.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments